Tesamorelina vs MK-677 (Ibutamoren)
Tesamorelina is mainly studied for visceral fat, body composition. while MK-677 (Ibutamoren) is studied for recovery, appetite, sleep, composition. The difference is in the mechanism and the evidence, not in which is "better": it depends on the goal.
| Tesamorelina | MK-677 (Ibutamoren) | |
|---|---|---|
| Category | Metabolic | Hormonal/Sexual |
| Studied for | Visceral fat, body composition. | Recovery, appetite, sleep, composition. |
| How it acts | An analog studied for its relationship with the growth-hormone axis and its association with visceral-fat reduction in clinical contexts. | An oral secretagogue studied for its relationship with sustained growth-hormone and IGF-1 signaling. |
| Evidence level | Human trials available | Human trials available |
How they differ
Although sometimes mentioned together, Tesamorelina and MK-677 (Ibutamoren) do not target the same thing. Tesamorelina: An analog studied for its relationship with the growth-hormone axis and its association with visceral-fat reduction in clinical contexts. MK-677 (Ibutamoren): An oral secretagogue studied for its relationship with sustained growth-hormone and IGF-1 signaling.
See full entry: Tesamorelina → · See full entry: MK-677 (Ibutamoren) →
Want to truly understand it, not memorize it?
The course explains each peptide at a university level: how it acts, what outcomes are studied, what it combines with and when to pause. No doses: the protocol is defined by a professional.
See the course → Start with the free test →Frequently asked questions
What is the main difference between Tesamorelina and MK-677 (Ibutamoren)?
Tesamorelina targets visceral fat, body composition. and MK-677 (Ibutamoren) targets recovery, appetite, sleep, composition. They act through different pathways, so the choice depends on your goal, not on which is "stronger".
Can they be studied together?
Combinations are studied by goal in the literature, but combining is not just adding: it changes the safety profile. What to combine and how is decided with a professional; here we only explain what each is studied for.
Which has more human evidence?
Based on the references we verified, Tesamorelina has more human studies of this pair. Each one's evidence level is in the table above, and the references with their PMID are at the end.
Other comparisons
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Tesamorelina vs MK-677 (Ibutamoren) or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
References
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Metabolic effects of a growth hormone-releasing factor in patients with HIVhuman N Engl J Med · 2007 · PMID 18057338 →
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionhuman J Acquir Immune Defic Syndr · 2010 · PMID 20101189 →
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data J Clin Endocrinol Metab · 2010 · PMID 20554713 →
- Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulationhuman AIDS · 2008 · PMID 18690162 →
- Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trialhuman Ann Intern Med · 2008 · PMID 18981485 →
- MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolismhuman J Clin Endocrinol Metab · 1998 · PMID 9467534 →
- Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient childrenhuman Clin Pharmacol Ther · 2001 · PMID 11452249 →
- Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trialhuman Neurology · 2008 · PMID 19015485 →
Educational content. It does not include doses, protocols or preparation: that is defined by a professional.